208 related articles for article (PubMed ID: 37366894)
1. HR+/HER2- Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review.
Jerzak KJ; Bouganim N; Brezden-Masley C; Edwards S; Gelmon K; Henning JW; Hilton JF; Sehdev S
Curr Oncol; 2023 Jun; 30(6):5425-5447. PubMed ID: 37366894
[TBL] [Abstract][Full Text] [Related]
2. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
4. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
[TBL] [Abstract][Full Text] [Related]
5. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
6. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors.
Burne R; Balu S; Guérin A; Bungay R; Sin R; Paul ML
J Med Econ; 2021; 24(1):806-815. PubMed ID: 34098827
[TBL] [Abstract][Full Text] [Related]
7. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
8. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Shah AN; Cristofanilli M
Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
[TBL] [Abstract][Full Text] [Related]
10. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Burris HA
Expert Rev Anticancer Ther; 2018 Mar; 18(3):201-213. PubMed ID: 29457921
[TBL] [Abstract][Full Text] [Related]
11. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
[TBL] [Abstract][Full Text] [Related]
12. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
[TBL] [Abstract][Full Text] [Related]
13. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
Johnston SRD; Harbeck N; Hegg R; Toi M; Martin M; Shao ZM; Zhang QY; Martinez Rodriguez JL; Campone M; Hamilton E; Sohn J; Guarneri V; Okada M; Boyle F; Neven P; Cortés J; Huober J; Wardley A; Tolaney SM; Cicin I; Smith IC; Frenzel M; Headley D; Wei R; San Antonio B; Hulstijn M; Cox J; O'Shaughnessy J; Rastogi P;
J Clin Oncol; 2020 Dec; 38(34):3987-3998. PubMed ID: 32954927
[TBL] [Abstract][Full Text] [Related]
14. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
[TBL] [Abstract][Full Text] [Related]
15. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
16. Ribociclib plus fulvestrant in the treatment of breast cancer.
Neven P; Sonke GS; Jerusalem G
Expert Rev Anticancer Ther; 2021 Jan; 21(1):93-106. PubMed ID: 33085548
[TBL] [Abstract][Full Text] [Related]
17. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
Sammons S; Shastry M; Dent S; Anders C; Hamilton E
Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
[TBL] [Abstract][Full Text] [Related]
18. Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Zangardi ML; Spring LM; Blouin GC; Bardia A
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1169-1176. PubMed ID: 28875723
[TBL] [Abstract][Full Text] [Related]
19. Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection.
Parati MC; Pedersini R; Perego G; Reduzzi R; Savio T; Cabiddu M; Borgonovo K; Ghilardi M; Luciani A; Petrelli F
Breast Cancer (Dove Med Press); 2022; 14():101-111. PubMed ID: 35440873
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]